Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells-Reference-Cited by-同舟云学术

Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

Published:2016-04-27 Issue:22 Volume:7 Page:33350-33362
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Dong Ling¹,Lv Huijuan¹,Li Wei¹,Song Zheng¹,Li Lanfang¹,Zhou Shiyong¹,Qiu Lihua¹,Qian Zhengzi¹,Liu Xianming¹,Feng Lixia¹,Meng Bin²,Fu Kai¹³,Wang Xi⁴,Pan-Hammarström Qiang¹⁵,Wang Ping⁶,Wang Xianhuo¹,Zhang Huilai¹

Affiliation:

1. Department of Lymphoma, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

2. Department of Pathology, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

3. Department of Pathology and Microbiology and Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

4. Department of Cellular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China

5. Department of Laboratory Medicine, Clinical Immunology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden

6. Department of Radiotherapy, Sino-US Center for Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring markers of immunoresponsiveness in papillary thyroid carcinoma and future treatment strategies;Journal for ImmunoTherapy of Cancer;2024-07

2. Is There an Immunohistochemical PD-L1 Cut-Off Point That Serves as a Prognostic Indicator for Large B-Cell Lymphomas?;Diagnostics;2024-05-31

3. Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy;International Journal of Molecular Sciences;2023-11-29

4. Clinical implications of aberrant PD-1 expression for acute leukemia prognosis;European Journal of Medical Research;2023-09-27

5. The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape;Cell Communication and Signaling;2023-06-27